Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025American Journal of Translational Research

GSK3 serves as a novel therapeutic target in patients with type 2 diabetes mellitus complicated by colorectal cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJixuan LuLSLijie SunXLXinyu LiCentral South University

Discussion

Loading...

Member takes

Implication

Analysis reveals GSK3β contributes to tumor progression in patients with type 2 diabetes, suggesting it as a therapeutic target.

Key Points

  • GSK3β is significantly upregulated in patients with type 2 diabetes and colorectal cancer, contributing to tumor progression.
  • Patients with type 2 diabetes show increased cancer incidence, with colorectal cancer being particularly prevalent.
  • Western blot and qRT-PCR validated elevated GSK3β levels in the insulin-resistant HT29 CRC cell line compared to non-resistant.
  • GSK3β silencing reduced tumor cell proliferation, indicating its potential as a therapeutic target in managing colorectal cancer.

Cite This Study

Lu et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d64791d0ahttps://doi.org/10.62347/tqud3910
View Full Paper
Ask AI
Bookmark
Share